Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT03800095 Recruiting - Clinical trials for Acute Myeloid Leukemia

Early Palliative Care for Patients With Haematological Malignancies

CALVI
Start date: March 14, 2019
Phase: Phase 3
Study type: Interventional

Patients suffering from haematological disease present symptoms of discomfort and currently benefit from palliative care skills only for the management of their end-of-life. However, in medical oncology, more and more studies tend to demonstrate the benefit on the quality of life of an early collaboration between the two specialties. Investigator did the hypothesis that early integration of palliative care with conventional haematological care could decrease discomfort symptoms and add a real benefit on the patients' quality of life .

NCT ID: NCT03797261 Terminated - Clinical trials for Acute Myeloid Leukemia

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Start date: March 18, 2019
Phase: Phase 1
Study type: Interventional

This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL)/diffuse large B-cell lymphoma (DLBCL). This study will include a dose escalation phase to identify the maximum tolerated dose/recommended phase 2 dose (MTD/RPTD) of venetoclax plus AMG 176 as well as a dose expansion phase to confirm safety, explore efficacy, and confirm the suitability of the preliminary RPTD.

NCT ID: NCT03795779 Recruiting - Clinical trials for Acute Myeloid Leukemia

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Start date: March 1, 2018
Phase: Early Phase 1
Study type: Interventional

Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CLL1-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.

NCT ID: NCT03793478 Recruiting - Clinical trials for Acute Myeloid Leukemia

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Start date: August 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.

NCT ID: NCT03790072 Completed - Clinical trials for Acute Myeloid Leukemia

Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)

Start date: November 27, 2018
Phase: Phase 1
Study type: Interventional

This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.

NCT ID: NCT03789981 Recruiting - Clinical trials for Acute Myeloid Leukemia

Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

Immune-AML
Start date: July 19, 2019
Phase:
Study type: Observational

This is a multicenter, prospective, translational study, to evaluate the immunogenic profile of AML cases according to immune checkpoint molecule expression.

NCT ID: NCT03769532 Recruiting - Clinical trials for Acute Myeloid Leukemia

MRD-guided Treatment in NPM1mut AML Patients

PEMAZA
Start date: August 21, 2019
Phase: Phase 2
Study type: Interventional

Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable residual disease (MRD).

NCT ID: NCT03760666 Terminated - Clinical trials for Acute Myeloid Leukemia

A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Start date: December 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects.

NCT ID: NCT03760523 Terminated - Clinical trials for Acute Myeloid Leukemia

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

Start date: April 18, 2019
Phase: Phase 1
Study type: Interventional

This study is to determine the safety and recommended dosing of Minnelide in Acute Myeloid Leukemia (AML)

NCT ID: NCT03755856 Recruiting - Clinical trials for Acute Myeloid Leukemia

Long-term Outcomes for Acute Myeloid Leukemia Patients

1621-QLG-LG
Start date: May 16, 2019
Phase:
Study type: Observational

This international observational study aims at examining the patterns of health-related quality of life differences between long-term acute myeloid leukemia patients and their healthy peers from the general population.